Published in Hum Mol Genet on November 01, 2000
Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest (2003) 2.60
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol (2008) 1.93
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.92
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) 1.63
Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol (2003) 1.53
Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta (2008) 1.51
Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett (2010) 1.40
Redox imbalance in Parkinson's disease. Biochim Biophys Acta (2008) 1.39
Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci (2012) 1.22
14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J (2005) 1.18
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. Pharmaceuticals (Basel) (2010) 1.13
The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity. J Biol Chem (2014) 0.96
Protein aggregation in retinal cells and approaches to cell protection. Cell Mol Neurobiol (2005) 0.96
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease. Nat Chem (2015) 0.94
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease. Antioxid Redox Signal (2016) 0.89
Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell Mol Neurobiol (2007) 0.89
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol (2001) 0.87
Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci (2010) 0.85
Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease. Proc Natl Acad Sci U S A (2016) 0.82
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation. J Bioenerg Biomembr (2014) 0.82
alpha-Synuclein: a therapeutic target for Parkinson's disease? Pharmacol Res (2008) 0.82
Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. Biomolecules (2015) 0.81
Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's Disease. Parkinsons Dis (2014) 0.80
Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics (2016) 0.80
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int (2010) 0.80
Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells. J Neural Transm (Vienna) (2011) 0.77
hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics (2016) 0.75
Parkinson's disease: genetics and beyond. Curr Neuropharmacol (2007) 0.75
Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Front Aging Neurosci (2017) 0.75
Role of Apolipoproteins and α-Synuclein in Parkinson's Disease. J Mol Neurosci (2017) 0.75
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Method of determining oxygen concentrations in biological media, suitable for calibration of the oxygen electrode. Anal Biochem (1970) 4.11
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 2.64
Variation in the N-terminal sequence of heavy chains of immunoglobulin G from rabbits of different allotype. Biochem J (1969) 2.59
Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage (2010) 2.39
Biological activities of lavender essential oil. Phytother Res (2002) 2.27
Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs (2002) 2.18
Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci (1999) 2.15
The metabolism of megestrol acetate (17-alpha-acetoxy-6-methylpregna-4, 6-diene-3, 20-dione) in the rabbit. Steroids (1965) 2.09
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
The regulatory proteins of the myofibril. Separation and biological activity of the components of inhibitory-factor preparations. Biochem J (1972) 2.06
The immunological activity of some of the chymotryptic peptides of sperm-whale myoglobin. Biochem J (1965) 1.94
Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci U S A (1998) 1.90
Allotypically related sequences in the Fd fragment of rabbit immunoglobulin heavy chains. Biochem J (1971) 1.90
Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol (1989) 1.88
The N-terminal sequence of the heavy chain of rabbit immunoglobulin IgG. Biochem J (1966) 1.85
The relationship between biological activity and primary structure of troponin I from white skeletal muscle of the rabbit. Biochem J (1976) 1.84
Mitochondria and degenerative disorders. Am J Med Genet (2001) 1.81
Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. J Neurol Sci (1992) 1.74
Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatry (2009) 1.70
Assembly of cytochrome-c oxidase in cultured human cells. Eur J Biochem (1998) 1.70
Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet (2000) 1.70
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem (1990) 1.66
Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol (1999) 1.63
A mutation in the human heme A:farnesyltransferase gene (COX10 ) causes cytochrome c oxidase deficiency. Hum Mol Genet (2000) 1.62
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem (1995) 1.61
Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. J Neurol Sci (1999) 1.59
Mammalian cytochrome-c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cells. Methods Enzymol (1995) 1.59
The preparation and properties of the components of troponin B. Biochim Biophys Acta (1974) 1.58
Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc Res (2001) 1.58
Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A (1999) 1.56
A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nat Genet (2001) 1.55
Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis (2010) 1.53
Comparison of amino acid sequence of troponin I from different striated muscles. Nature (1978) 1.52
Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet (2000) 1.51
Diagnostic value of succinate ubiquinone reductase activity in the identification of patients with mitochondrial DNA depletion. J Inherit Metab Dis (2002) 1.51
Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol (1993) 1.49
Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol (2000) 1.49
The phosphorylation sites of troponin I from white skeletal muscle of the rabbit. FEBS Lett (1974) 1.47
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol (2000) 1.47
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol (1992) 1.45
Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol (1992) 1.45
Hysteroscopic fluid monitoring guidelines. The ad hoc committee on hysteroscopic training guidelines of the American Association of Gynecologic Laparoscopists. J Am Assoc Gynecol Laparosc (2000) 1.44
Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41
Mitigating climate change: the role of domestic livestock. Animal (2010) 1.41
Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain (1992) 1.40
Calibration of pre-cut iridium-192 wires for low dose rate interstitial brachytherapy using a Farmer-type ionization chamber. Br J Radiol (2000) 1.40
Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology (2000) 1.40
Advances in the understanding of the cause of Parkinson's disease. J R Soc Med (1994) 1.39
Fully automatic segmentation of the proximal femur using random forest regression voting. IEEE Trans Med Imaging (2013) 1.39
Re: left portal vein as a direct source of gastric varices. Cardiovasc Intervent Radiol (1999) 1.38
Hunting for genes in essential tremor. Eur J Neurol (2008) 1.38
Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann Neurol (1998) 1.37
The chemical structure of the heavy chains of rabbit and human immunoglobulin G (IgG). Proc R Soc Lond B Biol Sci (1966) 1.36
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol (1994) 1.36
Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem (1994) 1.35
Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts. Pediatr Res (1987) 1.33
Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol (1998) 1.32
Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts: a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome. Biochim Biophys Acta (1997) 1.29
New insights into the cause of Parkinson's disease. Neurology (1992) 1.28
Sleep attacks (sleep episodes) with pergolide. Lancet (2000) 1.24
The AAGL classification system for laparoscopic hysterectomy. Classification committee of the American Association of Gynecologic Laparoscopists. J Am Assoc Gynecol Laparosc (2000) 1.24
High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl (1997) 1.21
The amino acid sequence of troponin I from rabbit skeletal muscle. Biochem J (1975) 1.21
A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy. Am J Hum Genet (1999) 1.20
Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol (1992) 1.19
Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol (1998) 1.18
Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci (1998) 1.18
Aromatic biosynthesis in yeast. I. The synthesis of tryptophan and the regulation of this pathway. Biochim Biophys Acta (1966) 1.18
Platelet mitochondrial function in Leber's hereditary optic neuropathy. J Neurol Sci (1994) 1.18
Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease. Cell Death Dis (2013) 1.17
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology (2006) 1.16
Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology (2004) 1.16
Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet (2000) 1.15